explore -WSS

explore

author：focus 2025-09-30 00:46:37 - browse：81

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Senators: Long

hotspot

Wikipedia

WSS

How AI helped researchers track recovery from depression

Intarcia’s device

Senate HELP committee spars over health care workforce policies

How AI helped researchers track recovery from depression

Ukraine and a new approach to mental health in war

Emergency workers more likely to restrain Black patients: study

leisure time

explore

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Former Georgia lieutenant governor says he received grand jury subpoena

State Dept. review finds Biden bears some blame for Afghanistan failures

Hearing on Medicare drug price negotiation gets unusually heated

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical records are filled with copy

Germany receives 178 compensation applications from gay servicepeople over discrimination

New air purifier tech could be key to improving indoor air quality

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

focus

Microbiome research is starting to find links to chronic diseases

Senate HELP committee spars over health care workforce policies

Experts study whether long Covid risk adds up with each reinfection

Ohioans vote in high

FDA panel to weigh approval of NurOwn, controversial ALS drug

Senators: Long

knowledge

hotspot

Wikipedia

explore